Effects of a cosmetic 'anti-ageing' product improves photoaged skin [corrected].

Dermatological Sciences Research Group, School of Translational Medicine, Faculty of Medical and Human Sciences, The University of Manchester, Oxford Road, Manchester, UK.
British Journal of Dermatology (Impact Factor: 3.76). 05/2009; 161(2):419-26. DOI: 10.1111/j.1365-2133.2009.09216.x
Source: PubMed

ABSTRACT Very few over-the-counter cosmetic 'anti-ageing' products have been subjected to a rigorous double-blind, vehicle-controlled trial of efficacy. Previously we have shown that application of a cosmetic 'anti-ageing' product to photoaged skin under occlusion for 12 days can stimulate the deposition of fibrillin-1. This observation infers potential to repair and perhaps clinically improve photoaged skin.
We examined another similar over-the-counter cosmetic 'anti-ageing' product using both the patch test assay and a 6-month double-blind, randomized controlled trial (RCT), with a further 6-month open phase to assess clinical efficacy in photoaged skin.
For the patch test, commercially [corrected] available test product and its vehicle were applied occluded for 12-days to photoaged forearm skin (n = 10) prior to biopsy and immunohistochemical assessment of fibrillin-1; all-transretinoic acid (RA) [corrected] was used as a positive control. Sixty photoaged subjects were recruited to the RCT (test product, n = 30 vs. vehicle, n = 30; once daily for 6-months; face & hands) [corrected] with clinical assessments performed at recruitment and following 1-, 3- & 6-months of use [corrected]. Twenty-eight subjects had skin biopsies (dorsal wrist) at baseline and at 6 months of treatment for immunohistochemical assessment of fibrillin-1 (test product, n = 15; vehicle, n = 13). All subjects [corrected] received test product for a further 6-months. Final clinical assessments were performed at the end of this open period; 27 subjects received test product for 12-months [corrected].
In the 12-day patch test assay, we observed significant immunohistological deposition of fibrillin-1 in skin treated by test product and RA as compared to untreated baseline (P = 0.005 and 0.015 respectively). In the clinical RCT, at 6 months, compared to baseline assessment, 43% of subjects on test product had an improvement in facial wrinkles (P = 0.013), whereas only 22% of subjects using vehicle had clinical improvement (P = ns). Between group comparison of test product and vehicle was non-significant (P = 0.10). After 12 months, there was a significant benefit of test product over that projected for vehicle (70% vs. 33% of subjects improving; combined Wilcoxon rank tests, P = 0.026). There was significant deposition of fibrillin-1 in skin treated for 6 months with test product (mean +/- SE; vehicle, 1.84 +/- 0.23; test product, 2.57 +/- 0.19; P = 0.019).
An over-the-counter cosmetic 'anti-ageing' product demonstrated clear benefit over vehicle in fibrillin-1 deposition over a 6-month trial period. There was a corresponding but non-significant trend towards clinical improvement in facial wrinkles. Clinical improvements in the treated group were increased after a further 6-months of use. This study demonstrates that a cosmetic may improve the appearance of wrinkles and further supports the use of fibrillin-1 as a robust biomarker for repair of photoaged dermis.

1 Bookmark
  • [Show abstract] [Hide abstract]
    ABSTRACT: Biomarkers and Ageing 25 February 2014, London, UK This conference was organized by Euroscicon and was part of the 2014 Ageing Summit. The central theme was biomarkers and aging including current research on biomarkers at the genomics and proteomics level. The informal atmosphere of the conference promoted interaction and networking opportunities between key leaders from industry, academic and clinics. Presentations as well as the discussion panel session brought opportunities to widely discuss the relevance of biomarkers as signatures for human aging or age-related diseases. The meeting highlighted the importance of genomics and regulatory elements in aging, their probable role in successful aging and their potential interest for future antiaging approaches. The meeting was chaired by David Melzer and Lorna Harries (University of Exeter, UK).
    Biomarkers in Medicine 06/2014; 8(5):621-3. · 3.22 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Dermal elastic fibres are extracellular matrix protein complexes produced by fibroblasts and involved in skin elasticity. Elastin fibres decrease with age as a result of reduced synthesis and increased degradation, resulting in skin sagging and reduced skin elasticity. In this study, we show that retinol (ROL), known to enhance dermal collagen production, is also enhancing elastin fibre formation. ROL induced elastin gene expression and elastin fibre formation in cultured human dermal fibroblasts. Topical treatment of cultured human skin explants with a low dose (0.04%) of ROL increased mRNA and protein levels of tropoelastin and of fibrillin-1, an elastin accessory protein, as documented by QPCR and immunohistochemistry staining. Luna staining confirmed the increased elastin fibre network in the ROL-treated skin explants, as compared with untreated controls. These data demonstrate that ROL exerts its anti-ageing benefits not only via enhanced epidermal proliferation and increased collagen production, but also through an increase in elastin production and assembly.
    International journal of cosmetic science 02/2011; 33(1):62-9.
  • British Journal of Dermatology 09/2009; · 3.76 Impact Factor

Full-text (2 Sources)

Available from
May 21, 2014